BRATISLAVA MEDICAL JOURNAL-BRATISLAVSKE LEKARSKE LISTY, cilt.121, sa.8, ss.547-553, 2020 (SCI-Expanded)
AIM: This study aims to compare the protective effects of ambrisentan, a selective endothelin typeA receptor antagonist, and bosentan, a dual endothelin typeA/B receptor antagonist, on experimental renal ischemia reperfusion injury.